{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T14:45:44Z","timestamp":1785422744032,"version":"3.56.0"},"reference-count":27,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004203","name":"Government of Ontario","doi-asserted-by":"publisher","award":["P.HSR.137"],"award-info":[{"award-number":["P.HSR.137"]}],"id":[{"id":"10.13039\/501100004203","id-type":"DOI","asserted-by":"publisher"}]},{"award":["P.HSR.137"],"award-info":[{"award-number":["P.HSR.137"]}],"id":[{"id":"https:\/\/ror.org\/015pzp858","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Chimeric antigen receptor (CAR) T-cell therapy is a new standard of care for patients with diffuse large B-cell lymphoma (DLBCL); however, studies including healthcare resource utilization (HRU) during routine care are lacking. Accordingly, a population-based study was conducted using linked administrative databases from Ontario, Canada. Patients with DLBCL that failed \u22652 lines of systemic therapy were included. Cox proportional hazard models estimated associations between covariates and overall survival (OS). Logistic, binomial and Poisson regression explored associations between covariates with toxicity and HRU. We identified 308 patients enrolled to receive CAR T-cell therapy of which 255 patients received CAR T-cells (mean age 59 years; 39% female). From the date of CAR T-cell infusion, the median OS was 25.0 months (95% CI, 21.6\u201328.1 months). Cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome data were available for 155 patients and were reported in 135 (87.1%) and 42 (27.1%) patients, respectively. Of those that received CAR-T cells, 172 patients (67%) were hospitalized with a median length of stay of 5 days (IQR, 0\u201320) and 243 (95%) had an emergency department visit without hospitalization. Our prospective population-based study demonstrates comparable efficacy and safety of CAR T-cell therapy in the real-world to the pivotal trials and highlights this as an efficacious and relatively safe treatment option for patients with DLBCL in routine clinical care.<\/jats:p>","DOI":"10.3390\/curroncol33060366","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T07:33:54Z","timestamp":1781768034000},"page":"366","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Prospective Population-Based Study of Chimeric Antigen Receptor T-Cell Therapy for Patients with Diffuse Large B-Cell Lymphoma"],"prefix":"10.3390","volume":"33","author":[{"given":"Lee","family":"Mozessohn","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Toronto, Toronto, ON M5S 3H2, Canada"},{"name":"ICES, Toronto, ON M4N 3M5, Canada"},{"name":"Odette Cancer Centre, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, ON M4N 3M5, Canada"},{"name":"Sunnybrook Research Institute, Toronto, ON M4N 3M5, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0944-1721","authenticated-orcid":false,"given":"Pierre J. A.","family":"Villeneuve","sequence":"additional","affiliation":[{"name":"The Ottawa Hospital, Ottawa, ON K1H 8L6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nibene H.","family":"Som\u00e9","sequence":"additional","affiliation":[{"name":"ICES, Toronto, ON M4N 3M5, Canada"},{"name":"Cancer Care Ontario, Ontario Health, Toronto, ON M5G 2M9, Canada"},{"name":"Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON M5T 3M6, Canada"},{"name":"Department of Epidemiology and Biostatistics, Western University, London, ON N6G 2M1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9264-7797","authenticated-orcid":false,"given":"Rebecca E.","family":"Mercer","sequence":"additional","affiliation":[{"name":"Sunnybrook Research Institute, Toronto, ON M4N 3M5, Canada"},{"name":"Canadian Centre for Applied Research in Cancer Control (ARCC), Toronto, ON M4N 3M5, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Masucci","sequence":"additional","affiliation":[{"name":"University Health Network, Toronto, ON M5G 2C4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Kouroukis","sequence":"additional","affiliation":[{"name":"Hamilton Health Sciences, McMaster University, Hamilton, ON L8N 3Z5, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Bredeson","sequence":"additional","affiliation":[{"name":"The Ottawa Hospital, Ottawa, ON K1H 8L6, Canada"},{"name":"Ottawa Hospital Research Institute, Ottawa, ON K1Y 4E9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suriya","family":"Aktar","sequence":"additional","affiliation":[{"name":"Cancer Care Ontario, Ontario Health, Toronto, ON M5G 2M9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Guan","sequence":"additional","affiliation":[{"name":"Cancer Care Ontario, Ontario Health, Toronto, ON M5G 2M9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anca","family":"Prica","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Toronto, Toronto, ON M5S 3H2, Canada"},{"name":"Princess Margaret Cancer Centre, Toronto, ON M5G 2C4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine I.","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Toronto, Toronto, ON M5S 3H2, Canada"},{"name":"Princess Margaret Cancer Centre, Toronto, ON M5G 2C4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8279-0621","authenticated-orcid":false,"given":"Danielle","family":"Rodin","sequence":"additional","affiliation":[{"name":"Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, ON M5G 2C4, Canada"},{"name":"Department of Radiation Oncology, University of Toronto, Toronto, ON M5G 2C4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew C.","family":"Cheung","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Toronto, Toronto, ON M5S 3H2, Canada"},{"name":"ICES, Toronto, ON M4N 3M5, Canada"},{"name":"Odette Cancer Centre, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, ON M4N 3M5, Canada"},{"name":"Sunnybrook Research Institute, Toronto, ON M4N 3M5, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munaza","family":"Chaudhry","sequence":"additional","affiliation":[{"name":"Cancer Care Ontario, Ontario Health, Toronto, ON M5G 2M9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8635-6889","authenticated-orcid":false,"given":"Scott","family":"Gavura","sequence":"additional","affiliation":[{"name":"Cancer Care Ontario, Ontario Health, Toronto, ON M5G 2M9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassandra","family":"McKay","sequence":"additional","affiliation":[{"name":"Cancer Care Ontario, Ontario Health, Toronto, ON M5G 2M9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William W. L.","family":"Wong","sequence":"additional","affiliation":[{"name":"School of Pharmacy, University of Waterloo, Waterloo, ON N2G 1C5, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelvin K. W.","family":"Chan","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Toronto, Toronto, ON M5S 3H2, Canada"},{"name":"ICES, Toronto, ON M4N 3M5, Canada"},{"name":"Odette Cancer Centre, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, ON M4N 3M5, Canada"},{"name":"Sunnybrook Research Institute, Toronto, ON M4N 3M5, Canada"},{"name":"Canadian Centre for Applied Research in Cancer Control (ARCC), Toronto, ON M4N 3M5, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1056\/NEJMra2027612","article-title":"Diffuse Large B-Cell Lymphoma","volume":"384","author":"Sehn","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/bmt.2016.213","article-title":"Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: An analysis of patients included in the CORAL study","volume":"52","author":"Schmitz","year":"2017","journal-title":"Bone Marrow Transplant."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/bmt.2015.213","article-title":"Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study","volume":"51","author":"Schmitz","year":"2016","journal-title":"Bone Marrow Transplant."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: Results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_7","first-page":"2307","article-title":"Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma","volume":"141","author":"Neelapu","year":"2023","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","article-title":"Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): A multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Schuster","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1200\/JCO.19.02103","article-title":"Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity","volume":"38","author":"Jacobson","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/ajh.25951","article-title":"Commercial anti-CD19 CAR T cell therapy for patients with relapsed\/refractory aggressive B cell lymphoma in a European center","volume":"95","author":"Sesques","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1038\/s41591-022-01969-y","article-title":"A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma","volume":"28","author":"Bachy","year":"2022","journal-title":"Nat. Med."},{"key":"ref_13","first-page":"349","article-title":"GLA\/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany","volume":"140","author":"Bethge","year":"2022","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1200\/JOP.2017.023697","article-title":"Can Chemotherapy-Related Acute Care Visits Be Accurately Identified in Administrative Data?","volume":"14","author":"Krzyzanowska","year":"2018","journal-title":"J. Oncol. Pract."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"mmrr.002.03.a05","DOI":"10.5600\/mmrr.002.03.a05","article-title":"Evaluating comorbidity scores based on health service expenditures","volume":"2","author":"Kilgore","year":"2012","journal-title":"Medicare Medicaid Res. Rev."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3448","DOI":"10.1002\/cncr.32295","article-title":"Identifying and characterizing cancer survivors in the US primary care safety net","volume":"125","author":"Hoopes","year":"2019","journal-title":"Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e009890","DOI":"10.1136\/jitc-2024-009890","article-title":"Real-world outcomes with tisagenlecleucel in aggressive B-cell lymphoma: Subgroup analyses from the CIBMTR registry","volume":"13","author":"Landsburg","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"404.e1","DOI":"10.1016\/j.jtct.2022.03.021","article-title":"Health Care Resource Utilization and Total Costs of Care Among Patients with Diffuse Large B Cell Lymphoma Treated with Chimeric Antigen Receptor T Cell Therapy in the United States","volume":"28","author":"Keating","year":"2022","journal-title":"Transplant. Cell. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1007\/s12325-024-02917-7","article-title":"Medicare Utilization and Cost Trends for CAR T Cell Therapies Across Settings of Care in the Treatment of Diffuse Large B-Cell Lymphoma","volume":"41","author":"Wu","year":"2024","journal-title":"Adv. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1182\/bloodadvances.2025017401","article-title":"Improved survival and healthcare utilization with CAR-T vs historical care in relapsed-refractory large B-cell lymphoma","volume":"10","author":"Kordbacheh","year":"2026","journal-title":"Blood Adv."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e355","DOI":"10.1016\/S2352-3026(21)00060-0","article-title":"Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): An international, multicentre, observational cohort study","volume":"8","author":"Azoulay","year":"2021","journal-title":"Lancet Haematol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/CCM.0000000000005149","article-title":"Critically Ill Patients Treated for Chimeric Antigen Receptor-Related Toxicity: A Multicenter Study","volume":"50","author":"Gutierrez","year":"2022","journal-title":"Crit. Care Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1080\/10428194.2024.2306463","article-title":"The impact of marginalization on diffuse large B-cell lymphoma overall survival: A retrospective cohort study","volume":"65","author":"Arya","year":"2024","journal-title":"Leuk. Lymphoma"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"4727","DOI":"10.1182\/bloodadvances.2024015634","article-title":"Inequalities in CAR T-cell therapy access for US patients with relapsed\/refractory DLBCL: A SEER-Medicare data analysis","volume":"9","author":"Chung","year":"2025","journal-title":"Blood Adv."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jtct.2022.04.008","article-title":"Socioeconomic and Racial Disparity in Chimeric Antigen Receptor T Cell Therapy Access","volume":"28","author":"Ahmed","year":"2022","journal-title":"Transplant. Cell. Ther."},{"key":"ref_27","first-page":"701","article-title":"Real-World Treatment Patterns and Out-of-Pocket Costs After CAR T-Cell Therapy in Commercially Insured Patients With B-Cell Non-Hodgkin Lymphoma in the United States","volume":"31","author":"Zuber","year":"2025","journal-title":"Transplant. Cell. Ther."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/6\/366\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T08:40:42Z","timestamp":1781772042000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/6\/366"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":27,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["curroncol33060366"],"URL":"https:\/\/doi.org\/10.3390\/curroncol33060366","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,18]]}}}